Login to Your Account



Biogen Selling Amevive Rights To Astellas For $60M, Royalties

By Jennifer Boggs


Wednesday, April 5, 2006
Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription